110.83
price up icon1.60%   1.75
 
loading
前日終値:
$109.08
開ける:
$110.1
24時間の取引高:
9.91M
Relative Volume:
1.19
時価総額:
$192.72B
収益:
$44.33B
当期純損益:
$6.48B
株価収益率:
29.93
EPS:
3.7033
ネットキャッシュフロー:
$6.92B
1週間 パフォーマンス:
+1.40%
1か月 パフォーマンス:
-13.26%
6か月 パフォーマンス:
-15.35%
1年 パフォーマンス:
-13.56%
1日の値動き範囲:
Value
$108.95
$111.06
1週間の範囲:
Value
$106.25
$111.06
52週間の値動き範囲:
Value
$105.27
$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name
名前
Abbott Laboratories
Name
セクター
Healthcare (1114)
Name
電話
(224) 667-6100
Name
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
職員
114,000
Name
Twitter
@AbbottNews
Name
次回の収益日
2026-01-22
Name
最新のSEC提出書
Name
ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Medical Devices icon
ABT
Abbott Laboratories
110.83 189.68B 44.33B 6.48B 6.92B 3.7033
Medical Devices icon
SYK
Stryker Corp
358.29 138.60B 25.12B 3.25B 4.28B 8.4018
Medical Devices icon
MDT
Medtronic Plc
102.90 131.98B 34.76B 4.79B 5.21B 3.7017
Medical Devices icon
BSX
Boston Scientific Corp
76.27 115.14B 20.08B 2.89B 3.82B 1.9391
Medical Devices icon
EW
Edwards Lifesciences Corp
78.71 45.32B 5.88B 1.34B 799.60M 2.3489

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-10 開始されました The Benchmark Company Buy
2025-07-18 アップグレード Jefferies Hold → Buy
2025-06-16 開始されました Leerink Partners Market Perform
2024-10-08 開始されました Oppenheimer Outperform
2024-09-19 開始されました Piper Sandler Overweight
2024-07-30 ダウングレード Edward Jones Buy → Hold
2024-05-30 開始されました Goldman Buy
2023-07-21 アップグレード Wolfe Research Underperform → Peer Perform
2023-05-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-04-20 繰り返されました Barclays Overweight
2023-04-20 繰り返されました Bernstein Outperform
2023-04-20 繰り返されました JP Morgan Overweight
2023-04-20 繰り返されました Raymond James Outperform
2023-04-20 繰り返されました UBS Buy
2023-04-20 繰り返されました Wolfe Research Underperform
2023-03-29 開始されました UBS Buy
2022-10-26 開始されました Mizuho Neutral
2022-10-18 開始されました Barclays Overweight
2022-10-12 開始されました Jefferies Hold
2022-07-06 開始されました Wolfe Research Underperform
2022-03-02 再開されました BofA Securities Buy
2022-01-27 繰り返されました Credit Suisse Outperform
2022-01-27 繰り返されました Morgan Stanley Overweight
2022-01-27 繰り返されました Raymond James Outperform
2022-01-27 繰り返されました UBS Buy
2021-12-10 開始されました RBC Capital Mkts Outperform
2021-10-27 アップグレード Atlantic Equities Neutral → Overweight
2021-10-14 開始されました Redburn Neutral
2021-05-25 開始されました Barclays Overweight
2021-04-15 開始されました Atlantic Equities Neutral
2021-01-28 アップグレード BTIG Research Neutral → Buy
2020-09-11 開始されました Wolfe Research Outperform
2020-06-01 ダウングレード Goldman Neutral → Sell
2020-03-05 開始されました Citigroup Buy
2020-02-13 開始されました Goldman Neutral
2020-02-06 再開されました BTIG Research Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-06-13 繰り返されました BofA/Merrill Buy
2019-02-07 繰り返されました BofA/Merrill Buy
2019-01-02 ダウングレード Citigroup Neutral → Sell
2018-11-30 アップグレード Goldman Neutral → Buy
2018-10-16 開始されました Barclays Overweight
2018-06-27 開始されました Bernstein Outperform
2018-01-30 繰り返されました Citigroup Neutral
2018-01-25 繰り返されました Stifel Buy
2018-01-25 アップグレード William Blair Mkt Perform → Outperform
2018-01-03 開始されました Evercore ISI Outperform
2018-01-02 アップグレード JP Morgan Neutral → Overweight
2018-01-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2017-10-19 繰り返されました RBC Capital Mkts Outperform
2017-10-19 繰り返されました Stifel Buy
すべてを表示

Abbott Laboratories (ABT) 最新ニュース

pulisher
04:48 AM

Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz

04:48 AM
pulisher
Feb 07, 2026

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²

Feb 07, 2026
pulisher
Feb 07, 2026

Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail

Feb 07, 2026
pulisher
Feb 07, 2026

Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks

Feb 07, 2026
pulisher
Feb 06, 2026

Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb

Feb 06, 2026
pulisher
Feb 06, 2026

Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News -

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India

Feb 06, 2026
pulisher
Feb 06, 2026

Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com India

Feb 06, 2026
pulisher
Feb 06, 2026

Catheter trials show Abbott devices cut AFib episodes for most patients - stocktitan.net

Feb 06, 2026
pulisher
Feb 05, 2026

UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech

Feb 05, 2026
pulisher
Feb 05, 2026

Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News

Feb 05, 2026
pulisher
Feb 05, 2026

BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail

Feb 05, 2026
pulisher
Feb 05, 2026

US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC

Feb 05, 2026
pulisher
Feb 05, 2026

Abbott Laboratories: How a 136-Year-Old Medtech Giant Is Re?Engineering the Future of Diagnostics an - AD HOC NEWS

Feb 05, 2026
pulisher
Feb 04, 2026

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

Feb 04, 2026
pulisher
Feb 04, 2026

US FDA says injuries from Abbott's recalled glucose sensors reach 860 - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

Abbott recalls glucose sensors after seven deaths linked to faulty readings - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus

Feb 04, 2026
pulisher
Feb 04, 2026

Abbott glucose monitor recall classified as most serious (ABT) - Seeking Alpha

Feb 04, 2026
pulisher
Feb 04, 2026

Do Wall Street Analysts Like Abbott Laboratories Stock? - Barchart.com

Feb 04, 2026
pulisher
Feb 04, 2026

FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech

Feb 04, 2026
pulisher
Feb 04, 2026

Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Abbott Laboratories Stock Now 18% Cheaper, Time To Buy - Trefis

Feb 04, 2026
pulisher
Feb 03, 2026

Gains Report: Can Abbott Laboratories sustain earnings growthDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott receives FDA warning letter related to FreeStyle Libre CGMs - MassDevice

Feb 03, 2026
pulisher
Feb 03, 2026

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered - The Motley Fool

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story - Yahoo Finance

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch - TechStock²

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott CEO Share Purchase Highlights $21b Exact Sciences Deal And Valuation - simplywall.st

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott receives FDA warning letter over Freestyle Libre CGMs - MedTech Dive

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure - Finviz

Feb 03, 2026
pulisher
Feb 03, 2026

OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.

Feb 03, 2026
pulisher
Feb 03, 2026

Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

Abbott Laboratories $ABT Stake Lessened by Thrivent Financial for Lutherans - MarketBeat

Feb 03, 2026
pulisher
Feb 02, 2026

Abbott Laboratories (ABT): A Bull Case Theory - Insider Monkey

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott (ABT) Sees Increased Bearish Options Activity - GuruFocus

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations - TechStock²

Feb 02, 2026
pulisher
Feb 02, 2026

The Best Dividend King to Buy With $150 - AOL.com

Feb 02, 2026
pulisher
Feb 02, 2026

ABT: Barclays Adjusts Abbott Laboratories Price Target to $142 | - GuruFocus

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott Laboratories (NYSE:ABT) Price Target Cut to $142.00 by Analysts at Barclays - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors - Seeking Alpha

Feb 02, 2026

Abbott Laboratories (ABT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
medical_devices SYK
$358.29
price down icon 1.14%
medical_devices MDT
$102.90
price down icon 0.05%
medical_devices BSX
$76.27
price down icon 1.76%
medical_devices EW
$78.71
price up icon 0.78%
$80.65
price down icon 2.02%
大文字化:     |  ボリューム (24 時間):